Swiss National Bank Has $2.01 Million Holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE)

Swiss National Bank grew its position in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 17.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 44,300 shares of the company's stock after buying an additional 6,600 shares during the quarter. Swiss National Bank owned approximately 0.10% of Apogee Therapeutics worth $2,007,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Intech Investment Management LLC bought a new stake in Apogee Therapeutics during the 3rd quarter worth approximately $300,000. Charles Schwab Investment Management Inc. boosted its stake in Apogee Therapeutics by 17.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 280,428 shares of the company's stock worth $16,472,000 after purchasing an additional 41,686 shares in the last quarter. FORA Capital LLC acquired a new position in Apogee Therapeutics in the third quarter worth $399,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Apogee Therapeutics during the third quarter worth $71,000. Finally, Vestal Point Capital LP acquired a new stake in shares of Apogee Therapeutics in the third quarter valued at $8,018,000. Institutional investors and hedge funds own 79.04% of the company's stock.

Insider Buying and Selling at Apogee Therapeutics

In other Apogee Therapeutics news, CEO Michael Thomas Henderson sold 10,000 shares of the business's stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $30.15, for a total value of $301,500.00. Following the completion of the transaction, the chief executive officer now directly owns 1,292,987 shares of the company's stock, valued at approximately $38,983,558.05. The trade was a 0.77 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Carl Dambkowski sold 4,085 shares of the stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $46.94, for a total value of $191,749.90. Following the completion of the sale, the insider now owns 255,348 shares of the company's stock, valued at $11,986,035.12. This trade represents a 1.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 49,195 shares of company stock valued at $2,026,392. Corporate insiders own 36.10% of the company's stock.

Remove Ads

Apogee Therapeutics Trading Up 4.6 %

Shares of APGE traded up $1.65 on Wednesday, reaching $37.26. 107,453 shares of the company's stock were exchanged, compared to its average volume of 490,966. The business has a 50 day moving average price of $37.50 and a two-hundred day moving average price of $45.75. Apogee Therapeutics, Inc. has a 12 month low of $29.10 and a 12 month high of $66.80. The stock has a market capitalization of $1.68 billion, a P/E ratio of -15.38 and a beta of 2.46.

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last issued its earnings results on Monday, March 3rd. The company reported ($1.19) EPS for the quarter, missing the consensus estimate of ($0.94) by ($0.25). Equities research analysts predict that Apogee Therapeutics, Inc. will post -3.09 EPS for the current year.

Analyst Upgrades and Downgrades

APGE has been the topic of several research reports. Wedbush reiterated an "outperform" rating and set a $90.00 price target on shares of Apogee Therapeutics in a research report on Tuesday, March 11th. Guggenheim reiterated a "buy" rating on shares of Apogee Therapeutics in a research report on Monday, February 10th. Finally, Citigroup started coverage on shares of Apogee Therapeutics in a research note on Thursday, March 13th. They set a "buy" rating and a $95.00 price target on the stock. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $92.17.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.